期刊
OBESITY SURGERY
卷 26, 期 4, 页码 843-855出版社
SPRINGER
DOI: 10.1007/s11695-015-1829-x
关键词
Gastric bypass surgery; Gastric bypass; Lipidaemia; Cholesterol; Triglycerides; NEFA
类别
Background Obesity-related dyslipidaemia comprises hypercholesterolaemia, hypertriglyceridaemia, low HDLcholesterol and normal to raised LDL-cholesterol levels. 40 % of morbidly obese surgical patients have dyslipidaemia. Roux-en-Y gastric bypass (RYGB) surgery has many beneficial metabolic effects, but the full impact on plasma lipids has not been clearly defined. Methods A systematic review of electronic databases (Ovid; Medline; PubMed; Embase) between 1960 and March 2012 was performed using search terms including the following: obesity surgery, bariatric surgery, gastric bypass, cholesterol, lipids, triglycerides and non-esterified fatty acids. A total of 2442 manuscripts were screened. Papers with paired plasma lipid levels around RYGB surgery were included. Exclusions included the following: editorials, dual publications, n< 10, resulting in 75 papers of relevance. A meta-analysis was performed of the effect of RYGB surgery upon plasma lipids at different time points up to 4 years following surgery, using a random effects model. Results Paired data were available for 7815 subjects around RYGB surgery for morbid obesity with a baseline BMI 48 kg/ m2 (n= 2331). There was a reduction in plasma total cholesterol and LDL-C from 1 month up to 4 years post-RYGB (p< 0.00001, p< 0.00001). Following RYGB, HDL-C increased from 1 year onwards (p< 0.00001), and triglyceride levels were reduced postoperatively from 3 months up to 4 years (p< 0.00001). NEFA levels were increased at 1 month postoperatively (p= 0.003), but from 3 months onwards did not differ from preoperative levels (p= 0.07). Conclusions RYGB surgery reverses the dyslipidaemia of obesity. These findings support the use of RYGB in the management of high cardiovascular risk lipid profiles in morbid obesity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据